Research
OriginalInvestigation
Cholecalciferol Treatment to Reduce Blood Pressure
in Older Patients With Isolated Systolic Hypertension
The VitDISH Randomized Controlled Trial
MilesD.Witham,PhD;RosemaryJ.G.Price,MSc;AllanD.Struthers,MD;PeterT.Donnan,PhD;
Claudia-MartinaMessow,PhD;IanFord,PhD;MarionE.T.McMurdo,MD
InvitedCommentary
IMPORTANCEObservationaldatalinklow25-hydroxyvitaminDlevelstobothprevalentblood
Supplementalcontentat
pressureandincidenthypertension.NoclinicaltrialhasyetexaminedtheeffectofvitaminD jamainternalmedicine.com
supplementationinisolatedsystolichypertension,themostcommonpatternof
hypertensioninolderpeople.
OBJECTIVE Totestwhetherhigh-dose,intermittentcholecalciferolsupplementationlowers
bloodpressureinolderpatientswithisolatedsystolichypertension.
DESIGN Parallelgroup,double-blind,placebo-controlledrandomizedtrial.
SETTING Primarycareclinicsandhospitalclinics.
PARTICIPANTS Patients70yearsandolderwithisolatedsystolichypertension(supinesystolic
bloodpressure>140mmHgandsupinediastolicbloodpressure<90mmHg)andbaseline
25-hydroxyvitaminDlevelslessthan30ng/mLwererandomizedintothetrialfromJune1,
2009,throughMay31,2011.
INTERVENTIONS Atotalof100000Uoforalcholecalciferolormatchingplaceboevery
3monthsfor1year.
MAINOUTCOMESANDMEASURES Differenceinofficebloodpressure,24-hourblood
pressure,arterialstiffness,endothelialfunction,cholesterollevel,insulinresistance,and
b-typenatriureticpeptidelevelduring12months.
RESULTS Atotalof159participantswererandomized(meanage,77years).Meanbaseline
officesystolicbloodpressurewas163/78mmHg.Meanbaseline25-hydroxyvitaminDlevel
was18ng/mL.25-HydroxyvitaminDlevelsincreasedinthetreatmentgroupcomparedwith
theplacebogroup(+8ng/mLat1year,P<.001).Nosignificanttreatmenteffectwasseenfor
mean(95%CI)officebloodpressure(−1[−6to4]/−2[−4to1]mmHgat3monthsand1[−2to
4]/0[−2to2]mmHgoveralltreatmenteffect).Nosignificanttreatmenteffectwasevident
foranyofthesecondaryoutcomes(24-hourbloodpressure,arterialstiffness,endothelial
function,cholesterollevel,glucoselevel,andwalkingdistance).Therewasnoexcessof
adverseeventsinthetreatmentgroup,andthetotalnumberoffallswasnonsignificantly AuthorAffiliations:Agingand
Health,UniversityofDundee,
lowerinthegroupreceivingvitaminD(36vs46,P=.24).
Dundee,UnitedKingdom(Witham,
Price,McMurdo);Departmentof
CONCLUSIONSANDRELEVANCE VitaminDsupplementationdidnotimprovebloodpressure ClinicalPharmacology,Universityof
ormarkersofvascularhealthinolderpatientswithisolatedsystolichypertension. Dundee,Dundee,UnitedKingdom
(Struthers);DundeeEpidemiology
andBiostatisticsUnit,Medical
TRIALREGISTRATION isrctn.orgIdentifier:ISRCTN92186858 ResearchInstitute,Universityof
Dundee,Dundee,UnitedKingdom
(Donnan);RobertsonCentrefor
Biostatistics,UniversityofGlasgow,
Glasgow,UnitedKingdom(Messow,
Ford).
CorrespondingAuthor:MilesD.
Witham,PhD,NinewellsHospital,
JAMAInternMed.doi:10.1001/jamainternmed.2013.9043 DundeeDD19SY,UnitedKingdom
PublishedonlineAugust12,2013. (m.witham@dundee.ac.uk).
E1
Downloaded From: http://archinte.jamanetwork.com/ by a Georgia State University User on 10/10/2013
Research OriginalInvestigation VitaminDforBloodPressureReduction
I
solatedsystolichypertension(ISH)isthemostcommon wasperformedusingaminimizationalgorithm,adminis-
formofhypertensioninolderpeople,1-4isassociatedwith teredbytheRobertsonCentreforBiostatistics(Glasgow
anincreasedincidenceofbothcerebrovascularandcar- ClinicalTrialsUnit,UniversityofGlasgow,UnitedKingdom)
diovascularevents,andisadriverofleftventricularhyper- usingatelephone-basedsystemtoconcealstudyallocation
trophy—itselfariskfactorforsuddencardiacdeathandheart frominvestigatorsandparticipants.Minimizationvariables
failure.5,6Antihypertensivetherapiesimprovecardiovascu- usedwerebaseline25OHDlevelaboveorbelow20ng/mL,
laroutcomesinISH,7-9butfewstudieshaveenrolledtypical baselinesystolicbloodpressureaboveorbelow160mmHg,
olderpatientswithmultimorbidity.3TherecentHyperten- baselineageolderoryoungerthan80years,andthepres-
sionintheVeryElderlytrial10confirmsthatthebenefitsof enceofdiabetesmellitus.Identical,maskedmedication
bloodpressurereductionextendtoselectedveryoldpa- bottleswereused;patientswereobservedingesting100000
tients,butdespitethisevidence,manyolderpatientsareun- U of oral cholecalciferol (Vigantol oil; Merck KgAA) or
dertreatedinpartbecauseofthetreatmentconstraintsim- matchingplacebo(Myglioloil;MerckKgAA)aftercomple-
posedbythepresenceofmultimorbidityandpolypharmacy tionofbaselineand3-,6-,and9-monthassessments.
andinpartbecauseoftheadverseeffectsinherentinmanyan-
tihypertensivemedications,includingdizzinessandfalls.New, PrimaryOutcomeMeasures
simple,safe,andinexpensivewaysoftreatingbloodpressure Alloutcomemeasureswereperformedbyresearcherswho
inolderpeoplearehighlydesirable. weremaskedtotreatmentallocation.Outcomes,includingve-
Low25-hydroxyvitaminD(25OHD)levelsarestronglyas- nepuncturefor25OHDlevels,wereallmeasuredonthesame
sociatedwithbothprevalentandincidenthypertension11-13and day,withtrialmedicationdosingoccurringthenextday.The
cardiovasculardisease14,15inobservationalstudies,andmeta- primaryoutcomemeasurewasprespecifiedasthebetween-
analysesofpreviousinterventiontrials16suggestthatvita- groupdifferenceinofficebloodpressureat3monthsana-
minDmayreducebloodpressureinselectedpatientgroups. lyzedusingallparticipantsregardlessofwhethertheyre-
TrialstodatehavenotevaluatedtheeffectsofvitaminDon ceivedtheirallocatedintervention.
ISH.WeconductedtheVitDISH(VitaminDinIsolatedSys-
tolicHypertension)randomizedcontrolledtrialtotestthe SecondaryOutcomeMeasures
effectofintermittent,high-dosecholecalciferolonblood 24-HourBloodPressure
pressureandmarkersofvascularfunctioninolderpatients The24-hourbloodpressurewasmeasuredusinganambula-
withISH. torymonitor(MeditechABPM-04;MeditechLtd)at0,3,6,9,
and12months.Themeanofthe24-hourrecordingwasused
asthemainmeasure;daytimeandnighttimereadingswerealso
analyzedseparately.Sensitivityanalysesusingaqualitythresh-
Methods
old(minimumof14daytimeand7nighttimereadingsper
DesignandParticipants the British Hypertension Society guidance17) were also
ResearchethicsapprovalwasobtainedfromtheFifeandForth performed.
ValleyNationalHealthServiceResearchEthicsCommittee(08/
S0501/90).Clinicaltrialsauthorizationwasobtainedfromthe SolubleMarkersofCardiovascularRisk
UKMedicinesandHealthcareRegulatoryAuthority(Euro- Solublemarkerswerecollectedatbaselineand3and12months
peanUnionDrugRegulatingAuthoritiesClinicalTrialsNo. afteraminimum6-hourfast.Sampleswerecollectedformea-
2008-004534-24).ThetrialsponsorwastheUniversityof surementofb-typenatriureticpeptide,high-sensitivity
Dundee,andthetrialwasregisteredatwww.controlled-trials C-reactiveprotein,andinsulinmeasurement.Insulinandglu-
.com(ISRCTN92186858).Thecompleteprotocolisavailable cosemeasurementswereusedtoconstructahomeostasis
fromtheauthors. modelassessmentofinsulinresistance18usingthefollowing
Thestudywasarandomized,double-blind,placebo- formula:(fastingglucoselevel×fastinginsulinlevel)/405.
controlled,parallel-grouptrial.Westudiedcommunity-
dwellingpatients70yearsandolderwithISH.Inclusioncri- EndothelialFunction
teriawereasfollows:ageof70yearsorolder,25OHDlevel Endothelialfunctionwasassessedat0,3,and12monthsby
lessthan30ng/mL(toconverttonanomolesperliter,multi- measuringflow-mediateddilatationofthebrachialarteryin
plyby2.496),andofficesystolicbloodpressuregreaterthan responsetohyperemia(endothelium-dependentvasodila-
140mmHg.Fullexclusioncriteriaanddetailedtrialmethods tion)after5minutesofforearmcuffocclusionusingstan-
aregivenintheeMethodsintheSupplement.Patientswere dardtechniques.19Meandiameterwasmeasuredduring
recruitedvia3routes:fromthecommunityviaprimarycare baselineacquisitionandwascomparedwiththemaximum
practices,viaanarticleinthelocalnewspaperaboutthere- diameterachievedaftercuffdeflation.Flow-mediateddila-
searchstudy,andviasecondarycareclinics(cardiovascularand tationwasthenexpressedasthepercentagechangefrom
medicinefortheelderly). baselinediameter.
Intervention PulseWaveVelocity
Participantsenrollinginthestudywereallocatedtointer- Carotid-radialpulsewavevelocityandaugmentationindex
ventionorplaceboina1:1ratio.Stratifiedrandomization weremeasuredusingtheSphygmocorapplanationtonom-
E2 JAMAInternalMedicine PublishedonlineAugust12,2013 jamainternalmedicine.com
Downloaded From: http://archinte.jamanetwork.com/ by a Georgia State University User on 10/10/2013
VitaminDforBloodPressureReduction OriginalInvestigation Research
etrysystem(AtCorMedical)at0,3,and12monthstogivein- thescreening,andofthese,159wererandomizedintothe
dicesofarterialstiffness.Augmentationindexispresentednor- trialfromJune1,2009,throughMay31,2011.Thelastvisit
malizedtoaheartrateof75/min. ofthelastpatientoccurredattheendofMay2012.Partici-
pantflowthroughthetrialisshowninFigure1.The159par-
OtherBiochemicalMeasurements ticipantsrandomizedhadameanageof76.8years,amean
Wemeasuredthelevelsofglucose,totalcholesterol,low- officebloodpressureof163/78mmHg,andonlyminordif-
densitylipoproteincholesterol,high-densitylipoprotein ferencesinbaselinecharacteristicsbetweenthe2groups
cholesterol,triglycerides,serumalbumin,calcium,parathy- (Table1).Recruitmentwasterminatedatthispointbecause
roidhormone(PTH),and25OHDonfastingbloodsamples. thedropoutratewaslowerthanprojectedandthetrialwas
Screeningsampleswereanalyzedinsmallbatchesbefore oncoursetoobtaintherequirednumberofcompleting
enrollmentinthetrialtoascertaintrialeligibility;follow-up participants.
sampleswerestoredandbatchanalyzedattheendofthe
trial.CalciumintakewasassessedatbaselineusingtheScot- EffectofInterventionon25OHDLevels
tishCollaborativeGroupFoodFrequencyQuestionnaire.20 Mean25OHDlevelsincreasedfromabaselinelevelof18ng/mL
to28ng/mLat6monthsintheinterventiongroupbeforepla-
ExerciseCapacityandFalls teauing.Asmall(3-ng/mL)increasewasseenby6monthsin
Exercisecapacitywasdeterminedby6-minutewalksat0,6, theplacebogroup;theoveralleffectestimateoftheinterven-
and12months.21Thewalktestwasperformedona25-mflat tionduringthe12-monthstudyperiodwasequivalenttoa
course,usingstandardizedencouragementevery2minutes. 7-ng/mLincreasein25OHDlevelsintheinterventiongroup.
Fallfrequencywasprospectivelyrecordedbypatientsusing DetailsareshowninFigure2.Adherencetostudymedication
monthlydiaries. washigh;301of303planneddoses(99%)wereingestedinthe
interventiongroup,and285of294planneddoses(97%)were
StatisticalAnalysis ingestedintheplacebogroup.Missingdoseswerewithheld
A2-sidedP<.05wasconsideredsignificantforallanalyses.For becauseofelevatedcalciumlevelorsuspectedmedicationad-
eachoutcomemeasure,repeated-measures,mixed-effects verseeffects;noparticipantdeclinedtoingestmedicationat
analyseswereconducted,withestimationandtestingofmain anytimepoint.
effectsoftreatmentallocation(ttest)andgroup×timeinter-
action(Ftests).Analysesforoutcomemeasuresatindividual PrimaryOutcomeMeasure
timepoints,includingtheprimaryoutcomemeasures,were Officesystolicbloodpressurewasnotstatisticallydifferentbe-
basedonanalysisofcovariance,adjustingforbaselinevalues tweentreatmentandplacebogroupsat3months(Table2).Of-
oftheresponsevariableandlevelsofthestratificationvari- ficesystolicbloodpressuredecreasedbyamean(SD)of2.7
ables.Analyseswerebasedonamodifiedintent-to-treatpopu- (12.5)mmHginthetreatmentgroupbetweenbaselineand3
lation(allparticipantswithbaselineandfollow-upvaluesof monthscomparedwithasmallermean(SD)decreaseof1.4
theresponsevariablebeinganalyzed).Wecalculatedunad- (14.9)mmHgintheplacebogroup.Thebetween-grouptreat-
justedmodelsandmodelsadjustedforbaselinevaluesofthe menteffectafteradjustingforcovariateswas−0.7mmHg(95%
outcomemeasureunderstudy,alongwithbaseline25OHD CI,−5.2to3.8mmHg;P=.76).Seasonofrecruitment(May-
level,baselinebloodpressure,thepresenceofdiabetes,and OctobervsNovember-April,reflectingpeakandtrough25OHD
age.Wealsoadjustedforuseofthiazidediureticsgiventhe levelsinpopulationstudies)didnotchangetheeffectoftreat-
knowneffectsofthesemedicationsoncalciummetabolismand mentonbloodpressureat3months;between-groupdiffer-
useofstatinsgiventheirknowninteractionwithvascular enceinsystolicbloodpressurechangewas−0.9mmHg(95%
healthandvitaminDmetabolism.Sensitivityanalyseswere CI,−5.3to3.5mmHg)afteradjustmentforseason.Nopartici-
conductedusingmultipleimputationtoaccountformissing pantchangedantihypertensivetherapybetweenbaselineand
dataandexcludingpatientswithchangesinantihyperten- 3months.
sivemedicationtypeordoseforbloodpressureanalyses.On
thebasisofbloodpressuredatafromapreviousvitaminDin- SecondaryOutcomeMesures
terventiontrialforhypertension,22wepoweredthestudyto Detailsofbloodpressurechangeineachgroupovertimeare
detecta7-mmHgbetween-groupdifferenceinsystolicblood giveninTable2.Nosignificantbetween-groupdifferencesin
pressurechangebetweenbaselineand3months,assumingan bloodpressureatanytimepointforeitherofficebloodpres-
SDchangeof18mmHg.Todetectthischangewith80%power sureordaytime24-hourbloodpressureandnosignificantbe-
atanαlevelof.05required73patientspergroup.Weorigi- tween-groupdifferencesonrepeatedmeasuresanalysiswere
nallyanticipatedadropoutrateof20%and,thus,aimedtore- found.Furtheranalysisthatexcludedparticipantswitha
cruit180patientsintothetrial. changeintheirantihypertensivemedication(1intheplacebo
groupand3inthevitaminDgroupby12months)revealedno
relevantchangeintheseresults.Daytime24-hourbloodpres-
sureresultsweresimilarafterexcludingrecordingsthathad
Results
fewerthan14daytimereadings.
Patients from 13 primary care practices were invited to Table3liststhechangesinotheroutcomemeasuresat
expressinterestinthetrial;atotalof341agreedtoattend eachtimepoint.Nosignificantchangeinserumcalcium
jamainternalmedicine.com JAMAInternalMedicine PublishedonlineAugust12,2013 E3
Downloaded From: http://archinte.jamanetwork.com/ by a Georgia State University User on 10/10/2013
Research OriginalInvestigation VitaminDforBloodPressureReduction
Figure1.CONSORTDiagramforParticipantFlowThroughtheTrial
2255Invited to participate from 8Given information via clinics
13 general practices
730Expressed interest in study 341Attended screening 22Expressed interest in study
via news article
Failed screening:
83BP too low
30BP too high
178Attended baseline visit 3 69 e2 G5 FO RH <D 4 > 075 ng/mL
5Other
3BP out of range
7Illness
7Withdrew consent
2End of recruitment
159Proceeded to randomization
80Randomized to vitamin D 79Randomized to placebo
1 3I Ull nn wes ils
ling to
1 1 3D I Ulle nna wet s ih ls
ling to
continue
continue
76 (95%)3-mo Visit 74 (94%)3-mo Visit
1Unwilling to 3Unwilling to
continue continue
75 (94%)6-mo Visit 71 (90%)6-mo Visit
2Illness 1Unwilling to
continue
73 (91%)9-mo Visit 70 (89%)9-mo Visit
0Dropouts 1Unwilling to
continue
73 (91%)12-mo Visit 69 (87%)12-mo Visit
BPindicatesbloodpressure;eGFR,estimatedglomerularfiltrationrate;and25OHD,25-hydroxyvitaminD.
levelswasnoted,andPTHlevelsdecreasedbyasmall(3.8 ExerciseCapacityandFalls
pg/mL)butsignificantamountintheinterventiongroup Exercisecapacityasmeasuredbya6-minutewalkdidnotin-
relativetoplacebo. creasebyaclinicallysignificantamountwithvitaminD
therapy;thebetween-groupdifferencecomparedwithbase-
SubgroupAnalyses linewas16m(95%CI,2to31m;P=.03)at6monthsand12m
Aseriesofhypothesis-generatingposthocinteractionanaly- (95%CI,−4to28m;P=.13)at12months.Therewerenonsig-
seswereconducted.Nosignificantinteractionwasfoundbe- nificantlyfewerfallsinthevitaminDgroupduringthe12-
tweenbaseline25OHDlevel,baselinesystolicbloodpres- monthstudyperiod(36vs46falls;hazardratio,0.77;95%CI,
sure,dietarycalciumintake,orPTHlevel(usedascontinuous 0.50to1.20;P=.24);thetimetofirstfallineachgroupwas
variables)andthetreatmenteffectofvitaminDonsystolic similar(P=.94bylog-ranktest)aswasthenumberofpartici-
bloodpressure.Asignificantinteractionwasnotedbetween pantsineachgroupfallingatleastonce(25intheinterven-
angiotensin-convertingenzyme(ACE)inhibitororangioten- tiongroupand26intheplacebogroup).
sinreceptorblocker(ARB)useandtreatmenteffect,witha
greatertreatmenteffectseeninthosealreadytakingACEin- Safety
hibitorsorARBmedication(−4mmHgvs+8mmHg,P=.02). Adverseeventsweresimilarinbothtrialarms,withnosig-
Nosignificantinteractionwasseenbetweentheeffectoftreat- nificantexcessofadverseeventsinanysubcategoryofevents
mentondiastolicbloodpressureandbaseline25OHDlevel,ACE (eTableintheSupplement).Oneparticipantineachgrouphad
inhibitororARBuse,baselinecalciumintake,orbaselinePTH anadjustedserumcalciumlevelgreaterthan10.6mg/dL(to
level. converttomillimolesperliter,multiplyby0.25)duringthe
E4 JAMAInternalMedicine PublishedonlineAugust12,2013 jamainternalmedicine.com
Downloaded From: http://archinte.jamanetwork.com/ by a Georgia State University User on 10/10/2013
Table1.BaselineCharacteristicsofRandomizedParticipants Figure2.EffectofInterventionon25-HydroxyvitaminD(25OHD)Levels
VitaminD Placebo
Group Group 40
Characteristic (n=80) (n=79) 36
Age,mean(SD),y 76.9(4.8) 76.7(4.5)
Male,No.(%) 40(50) 42(53)
BMI 28.5(5.0) 27.9(4.5)
Myocardialinfarction,No.(%) 5(6) 5(6)
Angina,PTCA,orCABG,No.(%) 20(25) 17(22)
Peripheralvasculardisease,No.(%) 5(6) 7(9)
Diabetesmellitus,No.(%) 11(14) 11(14)
StrokeorTIA,No.(%) 10(12) 8(10)
0
No.ofmedications,median(IQR) 4(3to6) 5(3to8) 0 6 9 12 15
No.ofantihypertensivemedications, 2(1to2) 2(1to2.5)
median(IQR)
RAASblockers,No.(%) 41(51) 50(63)
β-Blockers,No.(%) 23(29) 26(33)
Calciumchannelblockers,No.(%) 32(40) 35(44)
Diuretics,No.(%) 37(46) 31(39) study;neitherparticipanthadsymptomsorrequiredtreat-
ment.Similarly,3of80participants(4%)inthevitaminDgroup
Statins,No.(%) 41(51) 46(58)
and5of79participants(6%)intheplacebogrouphadanin-
25OHD,ng/mL 18(6) 18(6)
creaseincreatininelevelgreaterthan20%comparedwithbase-
PTH,pg/mL 5.3(2.9) 5.3(1.9)
lineduringthestudy.
Serum-adjustedcalcium,mg/dL 9.2(0.28) 9.2(0.32)
Creatinine,mg/dL 0.93(0.23) 0.92(0.25)
OfficeBP,mmHg
Discussion
Systolic 163(11) 162(10)
Diastolic 78(7) 77(8) Previousmeta-analyses16,23,24havesuggestedthatvitaminD
DaytimeBP,mean,mmHg
supplementationproducesamodestreductioninsystolicblood
Systolic 136(11) 133(11) pressurebetween2and4mmHg.Selectedgroupsofpatients
Diastolic 71(9) 67(12) (eg,patientswithtype2diabetesandpatientswithelevated
Pulsewavevelocity,m/s 8.8(1.2) 8.7(1.2) baselinebloodpressure)25,26havedemonstratedlargerim-
Flow-mediateddilatationofbrachial 5.1(2.7) 5.1(2.7) provementsinbloodpressurewithvitaminDsupplementa-
artery,No.(%)
tionof8to13mmHg.Mixedresultshavebeenreportedfor
Cholesterol,mg/dL
theeffectsofvitaminDonendothelialfunctionandb-typena-
Total 189(46) 193(42)
triureticpeptidelevels,althoughsignificanteffectswerere-
LDL 108(39) 108(39)
portedinsomestudies,22,25-31andonerecenttrialdidnotfind
HDL 62(15) 62(15)
any improvement in arterial stiffness with vitamin D
Triglycerides,mg/dL 115(53) 115(62) supplementation.32Previoustrialshavenotfoundsignifi-
Glucose,mg/dL 54(13) 54(16) canteffectsonlipidprofilewithvitaminD,33butinpatients
HOMA-IRindex 5.5(4.0) 4.5(3.7) withlow25OHDlevels,supplementationmayenhancetheef-
BNP,median(IQR),pg/mL 21(11-68) 44(21-90) fectofstatinsmetabolizedviathecytochrome3A4pathway.34
CRP,median(IQR),mg/L 2.0(1.0-4.2) 1.5(0.8-3.4) Severalexplanationsarepossibleforthelackofeffectof
6-Minutewalkdistance,m 398(94) 402(105) vitaminDseeninthisstudy.First,vitaminDmayhavenosig-
Dailymeancalciumintake,mg 1127(407) 1123(372) nificanteffectonbloodpressure.Theoveralleffectsizeseen
bycombiningsmalltrialstodateismodest,anditispossible
Abbreviations:BMI,bodymassindex(calculatedasweightinkilogramsdivided
byheightinmeterssquared);BNP,b-typenatriureticpeptide;BP,blood thatarealbiologicaleffectonbloodpressureisnotpresent.
pressure;CABG,coronaryarterybypassgraft;CRP,C-reactiveprotein; AsecondpossibilityisthatvitaminDmaynotreduceblood
HDL,high-densitylipoprotein;HOMA-IR,homeostasismodelassessmentof
pressureinthisspecificpatientgroup.VitaminDmaynot
insulinresistance;IQR,interquartilerange;LDL,low-densitylipoprotein;
25OHD,25-hydroxyvitaminD;PTCA,percutaneoustransluminalcoronary reversevascularstiffnessandcalcificationduringa1-yearpe-
angioplasty;PTH,parathyroidhormone;RAAS,renin-angiotensin-aldosterone riodormightonlyacteffectivelyatanearlierstageinthedis-
system;TIA,transientischemicattack. easeprocess.Hypertensioninolderpeopleischaracteristi-
SIconversionfactors:Toconvert25OHDtonanomolesperliter,multiplyby callynotduetoelevatedreninlevels(incontrasttoyounger
2.496;PTHtonanogramsperliter,multiplyby1;calciumtomillimolesperliter,
patients);ifvitaminDactspredominantlyviatherenin-
multiplyby0.25;creatininetomicromolesperliter,multiplyby88.4;total
cholesterol,LDL,andHDLtomillimolesperliter,multiplyby0.0259; angiotensin-aldosteronesystemashasbeenpreviously
triglyceridestomillimolesperliter,multiplyby0.0113;glucosetomillimolesper postulated,35-37thiscouldexplainthelackofeffectseen,es-
liter,multiplyby0.0555;BNPtonanogramsperliter,multiplyby1;andCRPto
peciallybecause50%to60%ofpatientswerealreadytaking
nanomolesperliter,multiplyby9.524.
ACEinhibitorsorARBs.
Lm/gn
,leveL
DHO52
VitaminDforBloodPressureReduction OriginalInvestigation Research
Vitamin D
Placebo
32
28
24
20
16
12
8
4
3
Time, mo
ErrorbarsindicateSD.
jamainternalmedicine.com JAMAInternalMedicine PublishedonlineAugust12,2013 E5
Downloaded From: http://archinte.jamanetwork.com/ by a Georgia State University User on 10/10/2013
Research OriginalInvestigation VitaminDforBloodPressureReduction
Table2.ChangesinOfficeBPatEachTimePointbyRandomizationGroup
SystolicBP DiastolicBP
Mean(SD) TreatmentEffect(95%CI) Mean(SD) TreatmentEffect(95%CI)
Variable VitaminD Placebo Unadjusted Adjusted VitaminD Placebo Unadjusted Adjusted
Officebloodpressure,
mmHg
Baseline 163(11) 162(10) …a … 78(7) 77(8) … …
3mo 161(15) 161(16) −1(−6to4) −1(−6to3) 77(8) 78(9) −2(−4to1) −2(−4to1)
6mo 161(16) 159(16) 1(−3to6) 1(−3to6) 78(9) 77(9) 1(−2to3) 1(−2to3)
9mo 164(16) 161(16) 3(−2to7) 3(−2to7) 78(9) 77(8) 1(−2to3) 1(−1to3)
12mo 163(18) 160(15) 2(−3to6) 2(−3to7) 78(9) 76(8) 1(−1to4) 2(−1to4)
Overalltreatment … … 1(−2to4) 1(−2to4) … … 0(−2to2) 0(−2to2)
effect(95%CI)
Pvaluefor … … .58 .54 … … .06 .03
group×time
interaction
Daytimeambulatory
BP,mmHg
Baseline 136(11) 133(11) … … 69(8) 68(9) … …
3mo 135(11) 134(9) −1(−4to2) −1(−4to2) 68(8) 69(8) −1(−3to1) −1(−2to1)
6mo 134(10) 132(12) −1(−4to3) 0(−4to3) 68(8) 68(9) 0(−2to2) 1(−1to2)
9mo 136(12) 132(10) 1(−2to4) 1(−2to5) 68(8) 68(9) 0(−2to2) 0(−2to2)
12mo 135(12) 133(12) 1(−2to4) 1(−2to5) 69(9) 68(9) 1(−1to3) 1(−1to3)
Overalltreatment … … 0(−3to2) 0(−2to2) … … 0(−2to1) 0(−1to2)
effect(95%CI)
Pvaluefor … … .46 .36 … … .58 .45
group×time
interaction
Abbreviation:BP,bloodpressure. aEllipsesindicatedatanotapplicable.
Table3.SecondaryOutcomeMeasures:AdjustedBetween-GroupTreatmentEffectatEachTimePointa
TreatmentEffect(95%CI)
Outcome Month3 Month6 Month9 Month12 Overall
FMD,% 0.0(−0.9to0.9) ND ND −0.7(−1.7to0.2) −0.4(−1.1to0.4)
Pulsewavevelocity,m/s −0.1(−0.5to0.3) ND ND −0.2(−0.6to0.2) −0.2(−0.5to0.2) Abbreviations:BNP,b-type
Cholesterol,mg/dL natriureticpeptide;CRP,C-reactive
protein;FMD,flow-mediated
Total −3(−11to4) 0(−8to7) −3(−11to4) −5(−12to3) −3(−9to2)
dilatation;HDL,high-density
LDL −2(−8to3) −1(−7to5) −3(−9to3) −5(−11to1) −3(−7to2) lipoprotein;HOMA-IR,homeostasis
HDL 0(−2to3) 0(−3to2) −1(−3to2) −2(−4to1) 0(−3to2) modelassessmentofinsulin
resistance;LDL,low-density
Triglycerides,mg/dL −7(−19to5) 1(−12to13) −2(−14to12) −1(−14to12) −3(−12to7)
lipoprotein;ND,notdone.
Fastingglucose,mg/dL −1(−5to3) ND ND 0(−3to4) 0(−3to3)
aAdjustedforbaselinevalueof
BNP,pg/mL 3(−27to32) ND ND 35(5to65) 18(−5to41) variable,age,25-hydroxyvitaminD
HOMA-IRindex −0.4(−1.3to0.4) ND ND 0.0(−1.1to1.1) −0.2(−1.0to0.6) level,thepresenceofdiabetes
mellitus,systolicbloodpressure,
CRP,mg/L −0.5(−3.0to2.0) ND ND 1.3(−1.2to3.8) 0.4(−1.7to2.5)
thiazideuse,andstatinuse.
Althoughofficebloodpressurereadingswereallinthehy- Athirdpossibilityisthatthedoseusedwasinsufficientor
pertensiverangeinthisstudy,meandaytimebloodpressures incorrect.Intermittentdosingmighttheoreticallyhavediffer-
weremarkedlylower,withalmost50%ofparticipantshaving entbiologicaleffectstodailydosing,andextrapolationfrom
adaytimemeansystolicbloodpressurelessthan135mmHg. observationaldatahassuggestedthat25OHDlevelshigherthan
Itispossiblethataproportionofpatientsthereforehadwhite- 30ng/mLarerequiredforoptimalhealth.38Thedoseusedin
coathypertension(ie,elevatedbloodpressurewhenmea- thisstudywassufficienttoraisemeannadirlevelsfrom18to
suredbyhealthcareprofessionalsbutlowerbloodpressure 28ng/mL,andsimilarintermittentdosesproducingsimilarin-
atothertimes),buttheknownhighprevalenceoforthostatic crementsin25OHDlevelshavecausedmarkedreductionsin
hypotensioninolderhypertensivepatientsmayalsohavecon- bloodpressureinsomepreviousstudies.22,25
tributedtothisdiscrepancy;officebloodpressureswerere- Afourthpossibilityisthatotherpermissivefactors,forin-
cordedinthesupineposition,whereasmostdaytimeambu- stance,adequatecalciumintake,arerequiredforvitaminDto
latoryreadingswouldberecordedintheseatedorstanding produceabeneficialeffectonbloodpressure.Patientsinthis
position. studyhadahighcalciumintake(mean,>1g/d).Itispossible
E6 JAMAInternalMedicine PublishedonlineAugust12,2013 jamainternalmedicine.com
Downloaded From: http://archinte.jamanetwork.com/ by a Georgia State University User on 10/10/2013
VitaminDforBloodPressureReduction OriginalInvestigation Research
thatvitaminDsupplementationhaslittleextraeffectincal- Limitationsofourstudyincluderecruitmentfromasingle
cium-repleteindividuals;calciumisitselfthoughttohavea healthboardareaandpatientsallbeingofwhiteethnicity,lim-
slightantihypertensiveeffect,39althoughapossibledeleteri- itinggeneralizability.Recentdataonthepharmacokineticsof
ousroleinprecipitatingcardiovasculareventsisthesubject vitaminDsuggestthatserum25OHDlevelspeakat7daysbe-
ofongoingcontroversy.40Wefoundnoevidenceofaninter- foredecreasing,withahalf-lifeofafewweeks.43,44Morefre-
actionbetweencalciumintakeandthedegreeofbloodpres- quentdoses(ie,monthlyorevery2months)wouldbemoreef-
sureloweringonsubgroupanalysistosupportthishypoth- fectiveatraisingandmaintainingserum25OHDlevels;thislarger
esis,however. doseofvitaminDcouldconceivablyhavehadaneffect.How-
Cholecalciferolwaswelltoleratedinthistrial,withnoin- ever,4-monthadministrationof100000Uofcholecalciferolwas
creaseinadverseeventscomparedwithplacebo.High-dose effectiveatincreasing25OHDlevelsandreducingfracturesin
cholecalciferolwasassociatedwithanincreaseinfallsinare- apreviouslargeosteoporosistrial,45afindingthatunder-
centtrial41;ourvitaminDgrouphadareassuringlylownum- pinnedourchoiceofdosetimingforthecurrenttrial.Ambula-
beroffalls,consistentwithpreviousdata.42Asmallimprove- torybloodpressurewassomewhatlowerthanexpected,which
mentwasseeninthe6-minutewalkdistanceinkeepingwith mayhavelimitedourabilitytodemonstratereductionsinam-
previoustrialresults;however,themagnitudeoftheeffectseen bulatorybloodpressure.Thesizeofourtrialmeansthatasmall
inthisstudywaslessthantheminimumclinicallyimportant beneficialeffectonbloodpressurestillcannotbeexcluded,but
differenceof20mforthe6-minutewalktest.21 theclinicalrelevanceofsuchsmallimprovements,atleastat
Ourstudyhasseveralstrengths.Theprojectedfinalevalu- anindividualpatientlevel,isquestionable.
ablesamplesizewasreached,andthemeanage(77years)was Ourresultsdonotlendsupporttoperforminglargeran-
considerablyolderthanthatseeninmosthypertensiontrials. domizedcontrolledtrialsaimedspecificallyatbloodpres-
Patientshadawiderangeofcomorbidityandconcomitant surereduction,atleastinthispatientgroup.Itisstillpos-
medicationuseand,thus,thestudypopulationreflectsthat sible,however,thatvitaminDsupplementationcouldhave
seenintherealworld.Despiteenrollingolderandsometimes beneficialeffectsoncardiovascularhealthvianon–blood
frailpatients,thedropoutratewasonly11%in12months.Base- pressureeffects,46andongoinglargerandomizedtrialsare
linepatientcharacteristicswerewellbalancedbetweenthe2 duetoreportonthisinthenextfewyears.Inthemeantime,
groups,andasubstantialincreasein25OHDlevelswasachieved ourresultsdonotsupporttheuseofhigh-dose,intermittent
withtheintervention. cholecalciferoltotreatISHinolderwhitepatients.
ARTICLEINFORMATION providedrecruitmentassistance,andValonaGouck comparisonofplaceboandactivetreatmentfor
AcceptedforPublication:May28,2013. (UniversityofDundee)providedsecretarial olderpatientswithisolatedsystolichypertension.
support. Lancet.1997;350(9080):757-764.
PublishedOnline:August12,2013.
doi:10.1001/jamainternmed.2013.9043. REFERENCES 9 Sy. sL toiu licL, HW ypan erg teJG ns, iG oo nn ing CL h,L iniu aG (S, yS st ta -e Cs hs ie nn a)JA;
AuthorContributions:Studyconceptanddesign: 1.FranklinSS.Hypertensioninolderpeople,part1. CollaborativeGroup.Comparisonofactive
Witham,Price,Struthers,Donnan,Ford,McMurdo. JClinHypertens(Greenwich).2006;8(6):444-449. treatmentandplaceboinolderChinesepatients
A D Anc oq anu ln yi as si int si ,o aFn no do rdf in,d tMa et rca pM: reW u tr ai dt th o ioa . nm o, fP dri ac te a, :S Wtr iu thth ae mrs ,, 2 h. ypC eh ro teb na sn ii oa nn iA nV t. hC eli en li dc ea rl lp y.ra Nc Eti nce g: lJis Mol ea dte .dsystolic w 19i 9th 8i ;s 16ol (a 1t 2e ,d ptsy 1)s :t 1o 8l 2ic 3h -1y 8p 2e 9rt .ension.JHypertens.
Struthers,Donnan,Messow,Ford,McMurdo. 2007;357(8):789-796. 10.BeckettNS,PetersR,FletcherAE,etal;HYVET
Criticalrevisionofthemanuscriptforimportant 3.DuprezDA.Systolichypertensionintheelderly: StudyGroup.Treatmentofhypertensioninpatients
intellectualcontent:Allauthors. addressinganunmetneed.AmJMed. 80yearsofageorolder.NEnglJMed.
Administrative,technical,andmaterialsupport:All 2008;121(3):179-184;e3. 2008;358(18):1887-1898.
authors. 4.PrimatestaP,PoulterNR.Hypertension 11.FormanJP,GiovannucciE,HolmesMD,etal.
ConflictofInterestDisclosures:DrWithamwas managementandcontrolamongEnglishadults Plasma25-hydroxyvitaminDlevelsandriskof
fundedbyaChiefScientistOfficeClinicianScientist aged65yearsandolderin2000and2001. incidenthypertension.Hypertension.
Fellowship.Wealsoacknowledgethefinancial JHypertens.2004;22(6):1093-1098. 2007;49(5):1063-1069.
supportofNationalHealthServiceResearch 5.GosseP.Leftventricularhypertrophyasa 12.FormanJP,CurhanGC,TaylorEN.Plasma
ScotlandthroughNationalHealthServiceTaysidein predictorofcardiovascularrisk.JHypertensSuppl. 25-hydroxyvitaminDlevelsandriskofincident
facilitatingthisresearch. 2005;23(1):S27-S33. hypertensionamongyoungwomen.Hypertension.
Funding/Support:Thisclinicaltrialwasfundedby 6.LiaoY,CooperRS,McGeeDL,MensahGA,Ghali 2008;52(5):828-832.
theChiefScientistOffice,ScottishGovernment, JK.Therelativeeffectsofleftventricular 13.ScraggR,SowersM,BellC.Serum
grantCZH/4/470.Thetrialsponsorwasthe hypertrophy,coronaryarterydisease,and 25-hydroxyvitaminD,ethnicity,andbloodpressure
UniversityofDundee. ventriculardysfunctiononsurvivalamongblack intheThirdNationalHealthandNutrition
RoleoftheSponsors:Neitherthesponsornorthe adults.JAMA.1995;273(20):1592-1597. ExaminationSurvey.AmJHypertens.
funderhadinfluenceovertheanalysis, 7.SHEPCooperativeResearchGroup.Prevention 2007;20(7):713-719.
interpretationofthedata,orpreparation,review,or ofstrokebyantihypertensivedrugtreatmentin 14.WangTJ,PencinaMJ,BoothSL,etal.VitaminD
approvalofthemanuscript.Boththefunderand olderpersonswithisolatedsystolichypertension: deficiencyandriskofcardiovasculardisease.
thesponsorcontributedtothedesignandconduct finalresultsoftheSystolicHypertensioninthe Circulation.2008;117(4):503-511.
ofthestudy,datacollection,anddata ElderlyProgram(SHEP).JAMA.1991;265(24):3255- 15.PittasAG,ChungM,TrikalinosT,etal.
management. 3264. Systematicreview:vitaminDandcardiometabolic
AdditionalContributions:LesleyMcFarlane,BSc 8.StaessenJA,FagardR,ThijsL,etal.TheSystolic outcomes.AnnInternMed.2010;152(5):307-314.
(UniversityofDundee),performedlaboratory HypertensioninEurope(Syst-Eur)Trial
analyses,theScottishPrimaryCareResearch Investigators.Randomiseddouble-blind
NetworkandTaysideClinicalResearchCentre
jamainternalmedicine.com JAMAInternalMedicine PublishedonlineAugust12,2013 E7
Downloaded From: http://archinte.jamanetwork.com/ by a Georgia State University User on 10/10/2013
Research OriginalInvestigation VitaminDforBloodPressureReduction
16.WithamMD,NadirMA,StruthersAD.Effectof arandomisedcontrolledtrial.NutrMetab renin-angiotensinsysteminhumans.Hypertension.
vitaminDonbloodpressure:asystematicreview CardiovascDis.2012;22(10):864-870. 2010;55(5):1283-1288.
andmeta-analysis.JHypertens.2009;27(10):1948- 27.TarcinO,YavuzDG,OzbenB,etal.Effectof 37.TomaschitzA,PilzS,RitzE,etal.Independent
1954. vitaminDdeficiencyandreplacementon associationbetween1,25-dihydroxyvitaminD,
17.O’BrienE,CoatsA,OwensP,etal.Useand endothelialfunctioninasymptomaticsubjects. 25-hydroxyvitaminDandtherenin-angiotensin
interpretationofambulatorybloodpressure JClinEndocrinolMetab.2009;94(10):4023-4030. system:theLudwigshafenRiskandCardiovascular
monitoring:recommendationsoftheBritish 28.HarrisRA,Pedersen-WhiteJ,GuoDH,etal. Health(LURIC)study.ClinChimActa.
HypertensionSociety.BMJ.2000;320(7242):1128- VitaminD supplementationfor16weeksimproves 2010;411(17-18):1354-1360.
1134. flow-medi3 ateddilationinoverweight 38.Bischoff-FerrariHA,GiovannucciE,WillettWC,
18.MatthewsDR,HoskerJP,RudenskiAS,Naylor African-Americanadults.AmJHypertens. DietrichT,Dawson-HughesB.Estimationofoptimal
BA,TreacherDF,TurnerRC.Homeostasismodel 2011;24(5):557-562. serumconcentrationsof25-hydroxyvitaminDfor
assessment:insulinresistanceandβ-cellfunction 29.WithamMD,DoveFJ,KhanF,LangCC,Belch multiplehealthoutcomes.AmJClinNutr.
fromfastingplasmaglucoseandinsulin JJ,StruthersAD.EffectsofVitaminD 2006;84(1):18-28.
concentrationsinman.Diabetologia. supplementationonmarkersofvascularfunction 39.DickinsonHO,NicolsonDJ,CookJV,etal.
1985;28(7):412-419. aftermyocardialinfarction:arandomised Calciumsupplementationforthemanagementof
19.CorrettiMC,AndersonTJ,BenjaminEJ,etal; controlledtrial(publishedonlineMarch27,2012). primaryhypertensioninadults.CochraneDatabase
InternationalBrachialArteryReactivityTaskForce. IntJCardiol.doi:10.1016/j.ijcard.2012.03.054. SystRev.2006;19(2):CD004639.
Guidelinesfortheultrasoundassessmentof 30.SchleithoffSS,ZittermannA,TenderichG, 40.BollandMJ,AvenellA,BaronJA,etal.Effectof
endothelial-dependentflow-mediatedvasodilation BertholdHK,StehleP,KoerferR.VitaminD calciumsupplementsonriskofmyocardial
ofthebrachialartery:areportoftheInternational supplementationimprovescytokineprofilesin infarctionandcardiovascularevents:meta-analysis.
BrachialArteryReactivityTaskForce.JAmColl patientswithcongestiveheartfailure:a BMJ.2010;341:c3691.
Cardiol.2002;39(2):257-265. double-blind,randomized,placebo-controlledtrial. 41.SandersKM,StuartAL,WilliamsonEJ,etal.
20.MassonLF,McNeillG,TomanyJO,etal. AmJClinNutr.2006;83(4):754-759. Annualhigh-doseoralvitaminDandfallsand
Statisticalapproachesforassessingtherelative 31.WithamMD,CrightonLJ,GillespieND,Struthers fracturesinolderwomen:arandomizedcontrolled
validityofafood-frequencyquestionnaire:useof AD,McMurdoME.TheeffectsofvitaminD trial.JAMA.2010;303(18):1815-1822.
c Ho er ar le tl hat Nio un trc .o 2e 0f 0fi 3ci ;e 6n (3ts ):a 3n 13d -t 3h 2e 1.κstatistic.Public s ou fp lifp ele inm oe ln dt ea rti po an tio en ntp sh wys iti hca hl efu arn tc ft aio iln ura en :dquality 4 D2 .V. iA tav men inel DlA a, nG dil vle its ap mie inW DJ, aG ni all le os gp uie esL fD o, rO’Connell
21.PereraS,ModySH,WoodmanRC,Studenski arandomizedcontrolledtrial.CircHeartFail. preventingfracturesassociatedwithinvolutional
SA.Meaningfulchangeandresponsivenessin 2010;3(2):195-201. andpost-menopausalosteoporosis.Cochrane
commonphysicalperformancemeasuresinolder 32.LarsenT,MoseFH,BechJN,HansenAB, DatabaseSystRev.2009;15(2):CD000227.
adults.JAmGeriatrSoc.2006;54(5):743-749. PedersenEB.Effectofcholecalciferol 43.IlahiM,ArmasLA,HeaneyRP.
22.WithamMD,DoveFJ,DryburghM,SugdenJA, supplementationduringwintermonthsinpatients Pharmacokineticsofasingle,largedoseof
MorrisAD,StruthersAD.Theeffectofdifferent withhypertension:arandomized, cholecalciferol.AmJClinNutr.2008;87(3):
dosesofvitaminD 3onmarkersofvascularhealthin placebo-controlledtrial.AmJHypertens. 688-691.
patientswithtype2diabetes:arandomised 2012;25(11):1215-1222.
c 2o 11n 9t .rolledtrial.Diabetologia.2010;53(10):2112- 3 vi3 ta. mW inan Dg sH u, pX pi la emN, eY na tn ag tioY n,P oe nn pg lD asQ m. aIn lf iplu iden pc re ofo ilf
es:
4 a hn o4 d r. mlR o oo n nm g e- sa teg arn fm to el v ri aE ar, siM a inta i gos ln ec si va i enM rysL e l, arC u rgi mp er ci da a on lc si eiC o, ote r fot pa il c.Short
23.PilzS,TomaschitzA,RitzE,PieberTR.Vitamin ameta-analysisofrandomizedcontrolledtrials. ergocalciferol(vitaminD)orcholecalciferol
Dstatusandarterialhypertension:asystematic LipidsHealthDis.2012;11:42.doi:10.1186/1476-511X- (vitaminD)intheelderly2 .JClinEndocrinolMetab.
review.NatRevCardiol.2009;6(10):621-630. 11-42. 2008;93(83 ):3015-3020.
24.WuSH,HoSC,ZhongL.EffectsofvitaminD 34.SchwartzJB.EffectsofvitaminD 45.TrivediDP,DollR,KhawKT.Effectoffour
supplementationonbloodpressure.SouthMedJ. supplementationinatorvastatin-treatedpatients: monthlyoralvitaminD (cholecalciferol)
2010;103(8):729-737. anewdruginteractionwithanunexpected supplementationonfra3 cturesandmortalityinmen
25.SugdenJA,DaviesJI,WithamMD,MorrisAD, consequence.ClinPharmacolTher. andwomenlivinginthecommunity:randomised
StruthersAD.VitaminDimprovesendothelial 2009;85(2):198-203. doubleblindcontrolledtrial.BMJ.
functioninpatientswithtype2diabetesmellitus 35.LiYC,KongJ,WeiM,ChenZF,LiuSQ,CaoLP. 2003;326(7387):469.
andlowvitaminDlevels.DiabetMed. 1,25-DihydroxyvitaminD 3isanegativeendocrine 46.MuscogiuriG,SoriceGP,AjjanR,etal.Can
2008;25(3):320-325. regulatoroftherenin-angiotensinsystem.JClin vitaminDdeficiencycausediabetesand
26.WithamMD,DoveFJ,SugdenJA,DoneyAS, Invest.2002;110(2):229-238. cardiovasculardiseases?presentevidenceand
StruthersAD.TheeffectofvitaminDreplacement 36.FormanJP,WilliamsJS,FisherND.Plasma futureperspectives.NutrMetabCardiovascDis.
onmarkersofvascularhealthinstrokepatients: 25-hydroxyvitaminDandregulationofthe 2012;22(2):81-87.
E8 JAMAInternalMedicine PublishedonlineAugust12,2013 jamainternalmedicine.com
Downloaded From: http://archinte.jamanetwork.com/ by a Georgia State University User on 10/10/2013
